123I-Interleukin-2 uptake in squamous cell carcinoma of the head and neck carcinoma

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 35, Issue 2, 2008, Pages 281-286

  Loose, David ^a   Signore, Alberto ^b,c   Staelens, Ludovicus ^d   Bulcke, Katia Vanden ^d   Vermeersch, Hubert ^a   Dierckx, Rudi Andre ^a,c   Bonanno, Elena ^e   Van De Wiele, Christophe ^a,c  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^d GHENT UNIVERSITY   (Belgium)

^e UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

Head and neck carcinoma; IL 2; Molecular imaging; TIL

Indexed keywords

INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR; IODINE 123;

ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER SURGERY; CANCER THERAPY; CD25+ T LYMPHOCYTE; CLINICAL ARTICLE; CLINICAL TRIAL; FEMALE; HEAD AND NECK CARCINOMA; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MALE; PROSPECTIVE STUDY; PROTEIN EXPRESSION; SCINTIGRAPHY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SQUAMOUS CELL CARCINOMA; STAINING; TUMOR ASSOCIATED LEUKOCYTE; TUMOR BIOPSY; TUMOR CELL; WHOLE BODY IMAGING;

ADULT; AGED; CARCINOMA, SQUAMOUS CELL; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; INTERLEUKIN-2; IODINE RADIOISOTOPES; MALE; MIDDLE AGED; RADIOPHARMACEUTICALS; RECOMBINANT PROTEINS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY;

EID: 38349107015     PISSN: 16197070     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00259-007-0609-9     Document Type: Article

References (27)

1. Wustrow T, Mahnke C. Causes of immunosuppression in squamous cell carcinoma of the head and neck. Anticancer Res 1996;16:2433-68.
2. Hoffmann T, Bier H, Whiteside T. targeting the immune system: novel therapeutic approaches in squamous cell carcinoma of the head and neck. Cancer Immunol Immunother 2004;53:1055-67.
3. Grande C, Firvida J, Navas V, Casal J. Interleukin-2 for the treatment of solid tumors other than melanoma and renal cell carcinoma. Anticancer Drugs 2006;17:1-12.
4. Airoldi M, De Stefani A, Marchionatti S, Pedani F, Gabriele P, Ragona R, et al. Survival in patients with recurrent squamous cell head and neck carcinoma treated with bio-chemotherapy. Head Neck 2001;23:298-304.
5. Cortesina G, De Stefani A, Galeazzi E, Cavallo G, Jemma C, Giovarelli M, et al. Interleukin-2 injected around tumor-draining lymph nodes in head and neck cancer. Head Neck 1991;13:125-131.
6. De Stefani A, Forni G, Ragona R, Cavallo G, Bussi M, Usai A, et al. Improved survival with perilymphatic interleukin 2 in patients with respectable squamous cell carcinoma of the oral cavity and oropharynx. Cancer 2002;95:90-7.
7. Maas R, Dullens H, Den Otter W. Interleukin-2 in cancer treatment: disappointing or (still) promising? A review. Cancer Immunol Immunother 1993;36:141-8.
8. Smith K. The quantal theory of how the immune system discriminates between "self and non-self". Med Immunol 2004;3:1-22.
9. Signore A, Picarelli A, Annovazzi A, Britton K, Grossman A, Bonanno E, et al. 123I-Interleukin 2: biochemical characterization and in vivo use for imaging autoimmune disease. Nucl Med Commun 2003;24:305-16.
10. Signore A, Chianelli M, Annovazzi A, Spagnoli L, Pozzilli P, Pallone F, et al. 123I-Interleukin 2 scintigraphy for the in vivo assessment of intestinal mononuclear cell infiltration in Crohn's disease. J Nucl Med 2000;41:242-9.
11. Trentin L, Zambello R, Bulian P, Cerutti A, Milani A, Pirone E, et al. Functional role of IL-2 receptors on tumor-infiltrating lymphocytes. Br J Cancer 1994;69:1046-51.
12. Boscia R, Chen K, Johnson J, Whiteside T. Evaluation of therapeutic potential of interleukin 2-expanded tumor-infiltrating lymphocytes in squamous cell carcinoma of the head and neck. Ann Otol Rhinol Laryngol 1988;97:414-21.
13. Boheim K, Denz H, Boheim C, Glassl H, Huber H. An immunohistologic study of the distribution and status of activation of head and neck tumor infiltrating leucocytes. Arch Otorhinolaryngol 1987;244:127-32.
14. Signore A, Annovazzi A, Barone R, Bonanno E, D'Alessandria, Chianelli M, et al. 99mTc-Interleukin 2 scintigraphy as a potential tool for evaluating tumor-infiltrating lymphocytes in melanoma lesions: a validation study. J Nucl Med 2004;45:1647-52.
15. Weidmann E, Sacchi M, Plaisance S, Heo DS, Yasumura S, Lin WC, et al. Receptors for interleukin 2 on human squamous cell carcinoma cell lines and tumor in situ. Cancer Res 1992;52:5963-70.
16. Reichert TE, Nagashima S, Kashii Y, Stanson J, Gao G, Dou QP, et al. Interleukin-2 expression in human carcinoma cell lines and its role in cell cycle progression. Oncogene 2000;19:514-25.
17. Yasumura S, Lin W, Weidmann E, Hebda P, Whiteside T. Expression of interleukin 2 receptors on human carcinoma cell lines and tumor growth inhibition by interleukin 2. Int J Cancer 1994;59:225-34.
18. Cortesina G, Sacchi M, Galeazzi E, Johnson JT, Whiteside TL. Interleukin 2 receptors on squamous cell carcinomas of the head and neck. Characterization and functional role. Acta Otolaryngol 1992;112:370-5.
19. Sacchi M, Snyderman CH, Heo DS, Johnson JT, d'Amico F, Herberman RB, et al. Local adoptive immunotherapy of human head and neck cancer xenografts in nude mice with lymphokine-activated killer cells and interleukin 2. Cancer Res 1990;50:3113-8.
20. Knerer B, Hulla W, Martinek H, Formanek M, Temmel A, Kornfehl J. IL-1 and TNF-alpha but no IL-2 expression is found in squamous cell carcinomas of the head and neck by RT-PCR. Acta Otolaryngol 1996;116:132-6.
21. Reichert T, Watkins S, Stenson J, Johnson J, Whiteside T. Endogenous IL-2 in cancer cells: a marker of cellular proliferation. J Histochem Cytochem 1998;46:603-11.
22. Tartour E, Laurent D, Mosseri V, Jaulerry C, Brunin F, Point D, et al. Soluble interleukin-2 receptor serum level as a predictor of locoregional control and survival for patients with head and neck carcinoma. Cancer 1997;79:1401-8.
23. Tartour E, Mosseri V, Jouffrov T, Deneux L, Jaulerry C, Brunin F, et al. Serum soluble interleukin-2 receptor concentrations as and independent prognostic marker in head and neck cancer. Lancet 2001;357:1263-4.
24. Shahabuddin S. Expression and release of IL-2 receptor and production of IL-2 by activated T lymphocyte subsets. J Clin Lab Immunol 1991;36:27-32.
25. Rabinowich H, Vitolo D, Altarac S, Herberman R, Whiteside T. Role of cytokines in the adoptive immunotherapy of an experimental model of human head and neck cancer by human IL-2 activated natural killer cells. J Immunol 1992;149:340-9.
26. Smith K. The interleukin-2 receptor. Annu Rev Cell Biol 1989;5:397-425.
27. 123I-Interleukin-2 and its response to diet. Eur J Nucl Med 2000;27:18-24.